Table 4.
Top 20 potential SUMO-2/3 targeting TFs after KSHV reactivation
| Rank | Name | Transfac | TFBS # (in TSS±500 bp) | Peak # of TFBS (in TSS±500 bp) | % of TFBS Peak (in TSS±500 bp) | Gene # | |||
|---|---|---|---|---|---|---|---|---|---|
| 0 h | 12 h | 0 h | 12 h | 0 h | 12 h | ||||
| 1 | STAT1 | V$STAT1_03 | 282 | 53 | 79 | 18.8% | 28.0% | 45 | 68 |
| 2 | ETS1 | V$CETS1P54_01 | 1587 | 337 | 397 | 21.2% | 25.0% | 296 | 353 |
| 3 | PBX1 | V$PBX1_01 | 220 | 28 | 55 | 12.7% | 25.0% | 28 | 54 |
| 4 | ATF2 | V$CREBP1_01 | 272 | 45 | 67 | 16.5% | 24.6% | 45 | 64 |
| 5 | CREB1 | V$CREB_01 | 666 | 124 | 164 | 18.6% | 24.6% | 114 | 152 |
| 6 | GABPA/NRF-2 | V$NRF2_01 | 1577 | 320 | 379 | 20.3% | 24.0% | 274 | 335 |
| 7 | ELK1 | V$ELK1_02 | 1667 | 336 | 382 | 20.2% | 22.9% | 285 | 328 |
| 8 | IRF-1 | V$IRF1_01 | 534 | 46 | 118 | 8.6% | 22.1% | 43 | 113 |
| 9 | STAT6 | V$STAT_01 | 570 | 92 | 122 | 16.1% | 21.4% | 85 | 110 |
| 10 | FOXO4 | V$FOXO4_02 | 456 | 28 | 97 | 6.1% | 21.3% | 28 | 75 |
| 11 | NFATC1/2/3/4 | V$NFAT_Q6 | 487 | 50 | 102 | 10.3% | 20.9% | 29 | 55 |
| 12 | ARID5B/MRF2 | V$MRF2_01 | 478 | 74 | 100 | 15.5% | 20.9% | 68 | 91 |
| 13 | IRF-2 | V$IRF2_01 | 601 | 48 | 125 | 8.0% | 20.8% | 63 | 93 |
| 14 | SRY | V$SRY_01 | 523 | 32 | 108 | 6.1% | 20.7% | 30 | 91 |
| 15 | HLF | V$HLF_01 | 438 | 69 | 90 | 15.8% | 20.5% | 66 | 85 |
| 16 | IRF-7 | V$IRF7_01 | 754 | 87 | 153 | 11.5% | 20.3% | 79 | 126 |
| 17 | MEF2A | V$MEF2_01 | 455 | 36 | 91 | 7.9% | 20.0% | 28 | 72 |
| 18 | GATA1 | V$GATA1_04 | 191 | 14 | 38 | 7.3% | 19.9% | 13 | 35 |
| 19 | POU3F2 | V$POU3F2_02 | 246 | 17 | 48 | 6.9% | 19.5% | 17 | 43 |
| 20 | USF1 | V$USF_C | 441 | 69 | 86 | 15.6% | 19.5% | 64 | 78 |
bold: transcription factor with evidence of SUMO modification.